/
/
/

RPG Life Sciences Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Jun 2025Mar 2025Dec 2024
₹196 Cr₹177 Cr₹180 Cr₹169 Cr₹143 Cr₹173 Cr
₹5 Cr₹12 Cr₹3 Cr₹5 Cr₹5 Cr₹3 Cr
₹200 Cr₹189 Cr₹183 Cr₹174 Cr₹148 Cr₹176 Cr
₹158 Cr₹150 Cr₹146 Cr₹139 Cr₹123 Cr₹129 Cr
₹48 Cr₹45 Cr₹43 Cr₹41 Cr₹31 Cr₹52 Cr
₹63 L₹39 L₹25 L₹13 L₹18 L₹12 L
₹41 Cr₹40 Cr₹29 Cr₹35 Cr₹135 Cr₹47 Cr
₹31 Cr₹30 Cr₹22 Cr₹26 Cr₹117 Cr₹35 Cr

Share Price Live Stats

Open (₹)2,611.40
Volume (₹)100.00
High (₹)2,611.40
Upper Circuit3,265.90
Low (₹)2,611.40
Lower Circuit2,177.30
Prev Close2,652.40
52W High (₹)3,082.00
Price2,611.40
52W Low (₹)1,733.00

Share Market Cap & Key Ratios Overview

M.Cap (₹)4401.20 Cr
Div. Yield (%)0.90
PE Ratio38.21
Debt to Equity0.03
Price to Book5.05
Book Value366.05
EPS (TTM)69.64
Face Value8.00
ROE (%)20.28

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
RPGLIFENSE
LTP
1W Low
1W High
Market cap (₹)
1963-21.8 (-1.10%)
1881.80
2183.80
4,56,833Cr
9555+88 (0.93%)
8750
10010
2,45,426Cr
4857-209 (-4.13%)
4711.50
5252.50
1,87,320Cr
1119.9-41.4 (-3.56%)
1086.40
1230
1,13,217Cr
1499+89.8 (6.37%)
1300
1523.50
1,12,212Cr
1784.8-130.2 (-6.80%)
1697.20
2024
1,01,155Cr
2321+132.6 (6.06%)
2004.50
2321
97,626Cr
2560.6+141.4 (5.84%)
2317
2560.60
96,859Cr
1279.8+125.4 (10.86%)
1151
1279.80
96,406Cr
1653.1-63.9 (-3.72%)
1603.50
1818.40
93,614Cr
2611.4-17.6 (-0.67%)
2509.10
2739
4,401Cr

Key Highlights of RPG Life Sciences Ltd’s P&L

In 2026-03-31, RPG Life Sciences Ltd reported total revenue of ₹733.1Cr, compared with ₹667.76Cr in 2025-03-31, reflecting RPG Life Sciences Ltd turnover.

Depreciation was ₹21.48Cr and finance costs were ₹1.77Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹154.2Cr in 2026-03-31 as compared to ₹232.88Cr in 2025-03-31.

Net Profit (PAT) was ₹115.17Cr in 2026-03-31 compared with ₹183.24Cr in 2025-03-31.

Earnings per share (EPS) were ₹69.64 in 2026-03-31, compared with ₹110.80 in 2025-03-31.